Simple research view

OGN · Organon & Co.

$13.63 -0.29% Sep 10 close

Detected setup Trend Only · Setup Score 96/100

Stand aside — setup invalidated

Setup score 96, but distribution days reach 5 or more — stand aside until the condition resets.

Ask about OGN

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$OGN

Organon & Co.

Organon & Co. is a mid-cap Pharmaceuticals: Major company in the Health Technology sector with a market cap of $4B.

Health Technology Pharmaceuticals: Major stock Stage 2 · Advancing Base 1

$13.63 latest close

Join to Watchlist $OGN Share card

Verdict · setup score 96/100 · data Sep 10 close · 1 session old

Stand aside — setup invalidated

Setup score 96, but distribution days reach 5 or more — stand aside until the condition resets.

Review six verdicts Inspect chart

Earnings

Normal technical setup

No sourced report date Event risk is not modelled for this symbol

Deterministic evidence

OGN-0.29%

Broad market · SPY-0.60%

Same completed session window ending 2026-09-10. +0.31 points vs SPY.

Session internals Weak

Rule: closed flat-to-down and in the bottom third of the range. Judged on internals, not on the size of the move.

Vs prior close-0.29% From the open-0.22% Range position0% GapNo gap

QQQ confirmationConfirming (-1.06%) SMH confirmationConfirming (-2.44%)

Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.

Price $13.63 -0.3% Sep 10 close

52W High $13.78 1.1% below high

Wks Since High 0w 1w today

Base Depth 1.1% at Sep 11 detection

RS Rank 86 percentile of scan

SMA 50 $13.62

Avg Vol 2,877,391

Rel Vol (Sep 10) 0.72×

More stats

52W Low $5.69

Tight Wks 13

Base B1

SMA 200 $10.38

RS Line vs High -4.1%

RS Line Slope +2.0% ▲

Group Rank #27/58

ADR% 0.3%

ATR(14) $0.03 (0.3%)

Vol Pace (live) N/A

U/D Vol 3.74

A/D Days 14A / 5D

A/D Rating A+

VDU Bars 0/10 d

Position in 52-week range 98thpercentile of the 52-week range

$5.69low

$13.78high

OGN Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for OGN.

Create Free Account

Technical Analysis Report Card

$OGN · $13.63 · as of 2026-09-10 · multi-factor read

/ 100

Technicals 61/100

Reference read from price & volume only — the verdict at the top of the page decides the action.

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating

Weekly ▬ Sideways / consolidating

Monthly ▬ Sideways / consolidating

Moving Averages

50-day$13.62 ↑

100-day$13.30 ↑

200-day$10.38 ↑

Bullish (50 > 200)

RSI (14)

Reading39.4 · Bearish

Bearish momentum — sellers in control.

MACD (12/26/9)

StateWeakening

Histogram-0.021

Weakening — MACD slipped below its signal line. Histogram contracting.

Bollinger Bands (20,2)

%B / Width-18% · 1.1%

Squeeze — volatility compressing

Piercing the lower band — capitulation or strong selling. Bands are squeezing — volatility is compressing, often a precursor to a sharp move.

Volume · Buyer vs Seller

Up/Down vol3.74 · Accumulation

Rel volume0.72×

Accumulation — volume is concentrated on up days; buyers dominate. Recent volume is expanding versus its baseline.

Support & Resistance

R · $13.7852-week high

Price · $13.63now

S · $13.45swing level

S · $8.51swing level

S · $6.50swing level

Fibonacci · Uptrend swing

23.6%$11.87

38.2%$10.69

50.0%$9.73

61.8%$8.78

78.6%$7.42

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.

Unlock the exact entry, stop-loss, profit target, and reward-to-risk for OGN — plus the full 500+ symbol scanner and Ask-the-Legends chat.

Start your 7-day free trial →

Above 200-day MA50/200 bullishVolume accumulationRS 88 (leader)

Want this read in a legend's voice? Ask a Legend about OGN

Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →

Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 5 of 6 legends are Watching — building, not yet a confirmed buy.

Minervini

Watch

Minervini C

Trend-template read: 7/10 pass; wait for the soft misses to improve.

Passing evidence

1.1 Price > 150-day MA AND 200-day MAPrice $13.63, MA150 $11.23, MA200 $10.38

1.2 150-day MA > 200-day MAMA150 $11.23 vs MA200 $10.38

Failing evidence

2. Quarterly EPS growth ≥ 25%From SEPA scan

2. ROE ≥ 17%From SEPA scan

7/10 checks

Method → Playbook → Ask →

O'Neil

Avoid

O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence

L: RS rank ≥ 80 (IBD leadership)RS rank 88

N: Near 52-week high or RS line new high1.1% below high | RS line new high: False

Failing evidence

C: Quarterly EPS acceleration ≥ 25%Data unavailable

A: Annual earnings & revenue qualityRev -2.9%

3/8 checks

Method → Playbook → Ask →

Weinstein

Watch

Weinstein B

Stage-analysis read: Stage 2 is present; 1 supporting checks need improvement.

Passing evidence

Stage 2 (Advancing phase) confirmedStage 2 (Advancing)

Price above 30-week MA (200-day proxy)Price $13.63 vs MA200 $10.38

Failing evidence

Volume expansion above averageVolume ratio 0.72x

6/7 checks

Method → Playbook → Ask →

Livermore

Watch

Livermore B

Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence

Price$13.63

Relative strengthRS 88

Failing evidence

Volume vs average0.72x

Pivotal point cleared on expanding volumeNot confirmed

4/6 checks

Method → Playbook → Ask →

Darvas

Watch

Darvas B

Box-theory read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence

Price$13.63

Relative strengthRS 88

Failing evidence

Volume vs average0.72x

Box top broken on heavy volumeNot confirmed

4/6 checks

Method → Playbook → Ask →

Wyckoff

Watch

Wyckoff B

Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence

Price$13.63

Relative strengthRS 88

Failing evidence

Volume vs average0.72x

Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending

4/6 checks

Method → Playbook → Ask →

Base & Breakout

Breakout follow-through

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Unlock Base & Breakout Tracking

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising

Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +5 A+

Minervini · Grade Card

Fundamentals & leadership quality — Minervini’s published criteria · 3/7 met

C 3/7 criteria

Separate score from the Minervini Trend Template (8/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.

✗ EPS acceleration ≥25% QoQ —

✗ Revenue growth ≥20% YoY -3%

✗ Gross margin ≥30% —

✗ ROE ≥17% —

✓ RS rating ≥80 (leadership) 88

✓ Stage 2 uptrend (Weinstein) Stage 2

✓ Within 25% of 52W high -1.1%

Method Playbook

Trade it like Weinstein EXACT LEVELS · PRO

Minervini O'Neil Livermore Weinstein Darvas Wyckoff

Weinstein B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.

Pivot

Pro level

Published-method rule: Use Stage 1 resistance and the rising 30-week moving average as the Stage 2 transition boundary.
Evidence: Canonical setup geometry is available with Pro.

Entry trigger

Pro level

Published-method rule: Require a Stage 2 breakout above resistance on expanding volume; avoid entries while the 30-week average is flat or falling.
Evidence: Canonical setup geometry is available with Pro.

Initial stop

Pro level

Published-method rule: Start below the breakout structure or Stage 1 support where a return to the base invalidates the Stage 2 transition.
Evidence: Canonical setup geometry is available with Pro.

Trail

Rule-based

Published-method rule: Trail beneath rising 30-week support or later higher swing lows while Stage 2 remains intact.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.

Exit / invalidation

Pro level

Published-method rule: Exit on a decisive 30-week support failure or a Stage 3/Stage 4 transition; never treat a failed Stage 2 break as healthy consolidation.
Evidence: Canonical setup geometry is available with Pro.

Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

Trend Only

96 setup score

RS Score 88

Trend template 8/8 ✓

Why This Setup?

Trend Only · schematic

The Universal Edge Check · context only

What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.

2/7 universals met

Risk is defined — not met No stop — undefined risk
Asymmetric reward — partly met No target set
Clear of earnings — partly met Report date unknown
Not chasing (in range) — partly met Pivot distance unknown
Volume confirms — partly met 0.7× average — light
A relative-strength leader — met RS rank 86
In a confirmed uptrend — met Stage 2 · Trend template 8/8

Why these seven? → The Universal Edge

Minervini Trend Template

8/8 ✓

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $13.63 vs SMA150 $11.23 / SMA200 $10.38

SMA 150 above SMA 200 SMA150 $11.23 vs SMA200 $10.38

SMA 200 trending up Slope +0.66 over 20 days

SMA 50 above SMA 150 & 200 SMA50 $13.62

Price above SMA 50 $13.63 vs SMA50 $13.62

30%+ above 52-week low +139.5% from $5.69

Within 25% of 52-week high -1.1% from $13.78

RS score above 70 RS 88

Fundamentals

52W Range

98%

Mkt Cap SEC

3.6B

Rev YoY

-3%

EPS TTM

$0.72

P/E TTM

18.9x

Float

263M

Company

Company profile

Organon & Co.

OGN · NYSE · Health Technology · Pharmaceuticals: Major

Weekly Context

Multi-timeframe signals from weekly bars

W. Trend

8/8

W. RS

100

W. Support

$5.69

W. Resist

$13.78

Weekly Structure

Trend Rising

Tight Weeks 13

Confirmation Constructive

Scan History

20× streak

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 10

Flat Base ✓ Gate

97 0.0%

Sep 09

Base Breakout ✓ Gate

97 -0.3%

Sep 09

Base Breakout ✓ Gate

96 -0.3%

Get the full picture on OGN

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.

Start 7-Day Free Trial